Research & Development
WOMEN’S HEALTH AS INVESTMENT CASE · PREECLAMPSIA HEALTH ECONOMICS · November 2026

Preeclampsia: an asymmetric investment opportunity?

Preeclampsia affects nearly 10% of US births and costs more than $28 billion for each year's cases. It can, however, be prevented. Yet it has no approved disease-modifying therapy and no recommended early risk screen.

Preeclampsia has the economic scale of breast cancer, where sustained investment in screening, molecular understanding and targeted therapies reduced mortality by more than 40%.

This is a call to replicate the success of precision medicine in preeclampsia.

~2,800 words14 min read

Disclosure: aitiologic GmbH develops an investigational preeclampsia risk-assessment test. The company collaborates with the Fetal Medicine Foundation, whose investigators are co-authors of the ASPRE and PREVENT-PE trials and of aitiologic’s feasibility study. Nothing here is clinical guidance or investment advice. The current US standard of care is risk-factor based assessment and low-dose aspirin as recommended by ACOG, SMFM and the USPSTF.1,2

KEY FINDINGS
  • Preeclampsia affects 325,000 US births each year, about one in 11. Each annual cohort carries a lifetime cost of more than $28 billion.3
  • It can be prevented. Aspirin reduces preterm preeclampsia by 62% in the ASPRE trial. Risk-based planned birth reduces term preeclampsia by 30% in PREVENT-PE.4,5
  • Prevention depends on knowing who is at risk. No first-trimester predictive test is FDA-authorized or recommended by ACOG. Uptake of prevention by low-dose aspirin remains limited.1,3
  • The field is uncrowded. Preeclampsia has no approved early risk-assessment test and no disease-modifying therapy. Breast cancer, a disease of the same scale, has several tests, more than 40 approved drugs and at least 15 companion diagnostics.6,7,8
  • Breast cancer shows the path. Screening has been in place since the 1970s. Molecular profiling identified HER2 linked to aggressive disease in 1987. The first HER2-targeted therapy and its companion test were approved together in 1998. Together these advances helped build a multi-billion dollar precision medicine market segment.9,10

01 / BURDEN$28 billion, counted properly for the first time.

In November 2026 the McKinsey Health Institute, together with the Gates Foundation, published the most complete costing of preeclampsia to date. Using commercial and Medicaid claims, it found the condition in about 1 in 11 US births: 325,000 of 3.6 million a year. Earlier estimates put prevalence at 5 to 8%. The lifetime cost for each year’s cohort of mothers and children exceeds $28 billion. About $8 billion is medical spending within a year of delivery. A further $16 to 18 billion is long-term medical cost, led by cardiovascular and chronic kidney disease, and societal costs add $2 to 3 billion.3 The previous reference figure was only $2.18 billion, a first-year estimate built on 2012 data.11 For most of a decade the field was priced at roughly a quarter of its first-year cost and less than a tenth of its lifetime cost.

The human account is as heavy. Preeclampsia is linked to 1,000 to 2,200 US stillbirths a year, and women who have had it show two to four times the later risk of cardiovascular disease, an association whose causal share is unsettled. Treatment remains limited to managing complications. No approved therapy halts or reverses the disease, and delivery remains the definitive treatment, often at the cost of prematurity.1,3

02 / PREVENTIONPrevention is the lever.

Effective prevention strategies exist, and randomized trials now show this for preterm and term subtypes.

Preterm disease, where the cost due to premature births sits. In the ASPRE trial, women identified as high risk by first-trimester screening took aspirin 150 mg nightly. Preterm preeclampsia fell from 4.3% to 1.6%, a 62% reduction.4 ACOG, SMFM and the USPSTF already recommend aspirin 81 mg daily from 12 to 28 weeks, ideally before 16, for women with one high-risk factor or more than one moderate-risk factor.2

Term disease, where the cases sit. At least three quarters of preeclampsia arises at term after 37 weeks.12 Aspirin did not significantly reduce it in ASPRE, and no drug has.4,5 The PREVENT-PE trial, published in December 2025, showed another route. About 8,000 women at two UK hospitals were randomized. Those screened at 35 to 36 weeks and found to have a risk of 1 in 50 or more were offered planned birth between 37 and 40 weeks, earlier for higher risk. Preeclampsia occurred in 3.9% of the intervention group and 5.6% of controls, a 30% reduction, with no increase in emergency cesarean delivery or neonatal unit admission.5 Term preeclampsia has moved from unpreventable to a matter of better management.

Neither result is US practice yet. ASPRE used a higher dose and a combined screening algorithm; PREVENT-PE was open-label and has not been replicated in the US. Both levers turn on the same thing: knowing accurately who is at risk, in the first trimester for aspirin and at latest at 35 to 36 weeks for planned birth. That is where prevention is rationed today. One large records study found that 8% of high-risk pregnancies received aspirin, and more than half of the women who went on to develop preeclampsia had not met the ACOG high-risk criteria.3

Part of that gap is early risk detection. Part is prescribing and adherence. The interventions are a generic tablet and a delivery date. The limiting step is identifying who needs them.

03 / THE GAPThe scale of breast cancer, without its tools.

The fair comparison for preeclampsia is breast cancer, the most common cancer among women: 321,910 new invasive cases expected in US women in 2026 and $29.8 billion in annual care costs, the highest of any cancer.13,14 The two diseases are of the same scale. What each field has to work with is not.

Preeclampsia and breast cancer, United States.
MeasurePreeclampsiaBreast cancer
New cases per year~325,000 births3321,910 invasive cases, 2026 estimate13
Economic burden$28 billion+ lifetime per annual cohort; $8 billion within a year of delivery3$29.8 billion annual care cost, 202014
Deaths per year1,000 to 2,200 stillbirths as well as considerable maternal deaths342,14013
ScreeningBlood pressure measurement and risk-factor assessment. No FDA-authorized first-trimester predictive test.2,15Mammography, recommended every two years from age 40 to 74.16
Biomarker tests2 FDA-authorized test systems, both sFlt-1/PlGF, for short-term prognosis in hospitalized women.17,18At least 15 FDA-authorized companion diagnostics that match patients to therapy.8
Approved drugsNo disease-modifying drug and none for prevention. Magnesium sulfate is approved to prevent and control of eclamptic seizures.6,19More than 40 for treatment; 2 for prevention, tamoxifen and raloxifene.7
Pipeline and marketA handful of candidates in clinical trials3300+ drugs in development worldwide; $24.8 billion US drug market, 202520,21

The two cost figures are built differently. One is the lifetime cost of a single year’s new cases; the other is a year’s spending on more than four million women living with the disease.13,14 They are comparable in order of magnitude, not to the decimal.

Breast cancer care runs on a chain: screening finds disease, molecular tests define it, and therapies are matched to the result. In preeclampsia the first and last links are completely missing. The two FDA-authorized tests assess short-term progression in women already in hospital; neither screens for the disease.17,18 Laboratory-developed predictive tests have reached the market, a first-trimester screen from Labcorp in 2024 and a second-trimester RNA test from Mirvie in 2025, but none is FDA-authorized for prediction and ACOG does not recommend biomarker screening.1,22,23

Capital has followed the same pattern. Women’s health drew about 6% of private healthcare investment between 2020 and 2025, $175 billion of $2.87 trillion, and women’s cancers took the majority share, roughly $119 billion.24 The largest disclosed venture financing rounds in preeclampsia are in the tens of millions.25,26 In contrast, oncology rounds of hundreds of millions are common.

04 / PRECEDENTA unique opportunity to extend the success of precision medicine beyond oncology.

Breast cancer shows what becomes possible when we connect early disease detection with molecular biology: identifying biologically distinct patient groups helped enable targeted therapies.

HER2 is the clearest case. In 1987 amplification of the HER2 gene was linked to earlier relapse and shorter survival.9 On 25 September 1998 the FDA approved trastuzumab together with HercepTest, the assay that identifies the patients it can help. It was the first companion diagnostic.10 HER2 also showed that a biomarker-defined population could deliver both survival gains and concentrated commercial value.21 Breast cancer mortality has fallen 44% since 1989, a decline credited to earlier detection and better treatment.13

From detection to targeted intervention.
StepBreast cancer precedentOpportunity in preeclampsia
Identify risk or disease earlyMammography detects disease before symptoms appearAssess risk in the first trimester, before clinical presentation
Understand molecular differencesHER2 amplification linked to aggressive disease, 19879Molecular signatures associated with different disease courses
Enable targeted interventionTrastuzumab and its companion test approved together, 199810Better-targeted prevention today; patient selection and monitoring for new therapies

Early risk stratification is the entry point. Molecular understanding follows and creates the opportunity for precision medicine.

05 / THE OPPORTUNITYWhy asymmetric, and why now.

Capital also stayed away largely because the opportunity was mispriced. Until this month the working cost figure was $2.18 billion. Additionally, developers cite maternal and fetal safety risk in trials and regulatory pathways that remain largely untested, and Medicaid covers about 41% of US births, which constrains pricing.3 Women’s health also sits outside most funding allocations: it received 8.8% of NIH grant spending from 2013 to 2023, and one widely cited analysis found that 1% of healthcare research and innovation goes to female-specific conditions beyond oncology.27,28

These are frictions, not verdicts on the market, and several are easing. Moreover, three features make the opportunity particularly interesting:

  • Prevention is proven but under-delivered. Two randomized trials show preeclampsia can be prevented, for preterm and term disease, in women correctly identified as high risk.4,5
  • The distribution for first-trimester risk screening is already built. ACOG recommends that prenatal genetic screening, including cell-free DNA, be offered to every pregnant patient.29 A validated preeclampsia test on the same blood draw would need no new visit. Cell-free DNA is established for aneuploidy; for preeclampsia it is not, and that validation is the work to be funded.
  • The field is uncrowded. A marginal dollar in breast cancer competes with more than 300 programs.20 In preeclampsia it can fund a first in class. McKinsey estimates that a disease-modifying therapy with 50% efficacy in early-onset disease could avoid up to $5.4 billion of a $10.7 billion modelled burden, a theoretical ceiling.3

The timing has changed too. The cost is now explicitly documented in claims data. The WHO published a ten-year roadmap for hypertensive disorders of pregnancy in October 2026.6 The Gates Foundation committed $2.5 billion to women’s health R&D through 2030 and named preeclampsia among its targets.28 The FDA authorized the first angiogenic biomarker test in 2023 and a second in 2025, both for short-term prognosis in women already hospitalized with a hypertensive disorder.17,18 The first therapy aimed at the same pathway holds Fast Track designation, is in early clinical development and plans to use the FDA-authorized test to determine trial eligibility.30

Some venture investors have started to move. The wider market, however, has not: women’s health venture funding in the US and Europe fell by nearly 40% in 2025.31

06 / COUNTERPOINTSThe serious objections, taken seriously.

“ACOG does not recommend biomarker screening for preeclampsia.”

Correct, largely stating missing proof for clinical utility. Similarly, the USPSTF recommends screening by risk factors and blood pressure measurement.15 We think the bar for clinical utility is the right one. A first-trimester test should earn a recommendation by three things: prospective, blinded validation in US populations; performance reported as detection and false-positive rates, not as a single AUROC; and evidence that acting on the result improves outcomes. Nobody has yet funded that evidence at scale. That is the investment case, not an argument against the guideline.

“Breast cancer kills 42,000 women a year. Preeclampsia kills only a fraction.”

True, and it justifies much of the difference.13 Mortality is one measure of burden among several. Preeclampsia’s toll falls on stillbirths, preterm infants and decades of maternal cardiovascular disease. No weighting of those measures arrives at zero approved screening tests and zero approved therapies.

“The cost figures are not like for like.”

Correct. One is incidence-based and current; the other is prevalence-based and dates from 2020, and breast cancer drug spending has roughly doubled since.21 Most of the preeclampsia total is long-term cost that assumes later cardiovascular and kidney disease is attributable to preeclampsia. On the strictest count, the $8 billion spent within a year of delivery, preeclampsia still sits beside kidney cancer ($9.7 billion), bladder cancer ($9.4 billion) and ovarian cancer ($6.4 billion) each receiving significantly more investment as well.3,14 The claim is one of scale, not of equality.

“Breast cancer is oncology. The analogy does not transfer.”

In part, correct. A tumor can be biopsied and its drivers targeted. Preeclampsia involves two patients, a window of months and a placenta that is not routinely sampled. A signature that predicts disease is not yet a drug target. However the analogy is relevant: defining who is at risk, and how their disease differs on the molecular level, gives therapy something to aim at.

“Give everyone aspirin instead.”

Universal prophylaxis is a strategy that guidelines have not adopted.2 Adherence is its weak point. We address it in a companion paper.32

07 / SYNTHESISIs preeclampsia an asymmetric opportunity? Yes, on conditions.

Asymmetry applies twice. The allocation is asymmetric: a disease of breast cancer’s scale with no approved disease-modifying therapy, no recommended early test and little private capital. The payoff may be asymmetric as well: a documented high cost, prevention with randomized evidence for preterm and term subtypes, an uncrowded field and an existing distribution channel.

The conditions matter. No first-trimester biomarker test is recommended by ACOG today.1 However, the evidence bar in pregnancy is high, and should be. Investors who cannot underwrite those risks will rightly stay out. Those who can are buying into a $28 billion problem at early-stage prices.

Breast cancer shows what becomes possible when disease detection is connected with molecular biology. Preeclampsia should not follow the same path step for step. In the United States it has yet to take the first one: a validated, recommended way to identify who is at risk early enough to act.

WHERE AITIOLOGIC FITS

Earlier risk assessment can support prevention today. Molecular understanding can enable more targeted interventions tomorrow.

aitiologic is developing its aitios® precision medicine platform to connect these opportunities. Our lead application, aitios® NIPPT (Non-Invasive Prenatal and Preeclampsia Test), is a cell-free DNA liquid biopsy designed to combine standard non-invasive prenatal testing with first-trimester preeclampsia risk assessment from a single blood draw at 10–14 weeks. The test is investigational: it is not FDA-cleared or CE-marked and is not available for clinical use.

In a recent study with the Fetal Medicine Foundation, aitios® achieved AUROCs of 0.85 for preterm and 0.84 for term preeclampsia. In the same dataset, risk-factor assessment using ACOG-recommended criteria achieved 0.59 and 0.61, respectively; the FMF multiparameter first-trimester score, incorporating ultrasound and biomarker measurements, achieved 0.80 and 0.53.33 These findings support further investigation, not a claim of clinical superiority or improved outcomes. The study was exploratory and AUROC measures discrimination, not clinical benefit. Larger-scale validation is under way, and prospective US studies are in preparation.

The opportunity extends beyond a risk score. aitios® combines multimodal cfDNA analysis with AI for early risk stratification and non-invasive tissue-specific molecular insights into placental and broader organ health. Linking these signals to adverse pregnancy outcomes could help distinguish biological subtypes, generate therapeutic hypotheses and identify patient groups for clinical trials. Each application requires validation, but together they offer a path from screening toward precision prevention and treatment.

Realizing this opportunity requires investment in both the test and the evidence connecting its results to better care. We therefore make three asks:

  • Professional societies: Specify the evidence needed to incorporate a first-trimester risk assessment test into care, including the clinical actions and maternal and neonatal outcomes that would justify a change in guidance.
  • Payers: Define a transparent route to reimbursement and coverage, with explicit clinical utility and economic evidence requirements.
  • Investors and big pharma: Treat preeclampsia as the core healthcare opportunity it is. Fund the validation and clinical utility studies needed for adoption, alongside partnerships connecting molecular stratification with preventive and therapeutic development – building on the model that helped expand breast cancer into a major precision medicine market over recent decades.

References

  1. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.
  2. American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. ACOG Practice Advisory; December 2021.
  3. El Turabi A, Petersen A, Pérez L, et al. Beyond delivery: The human and economic toll of preeclampsia in the US. McKinsey Health Institute; November 2026.
  4. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
  5. Goadsby J, Syngelaki A, Magee LA, et al. Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial. Lancet. 2026;407(10523):67–77.
  6. World Health Organization. New global roadmap launched to tackle hypertension in pregnancy, a leading cause of maternal and newborn deaths. World Health Organization; 8 October 2026.
  7. National Cancer Institute. Drugs approved for breast cancer. National Cancer Institute; updated 23 September 2026.
  8. US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). US Food and Drug Administration; current as of 3 November 2026.
  9. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
  10. Jørgensen JT, Winther H, Askaa J, et al. A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Front Oncol. 2021;11:676939.
  11. Stevens W, Shih T, Incerti D, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017;217(3):237–248.e16.
  12. Magee LA, Wright D, Syngelaki A, et al. Preeclampsia prevention by timed birth at term. Hypertension. 2023;80(5):969–978.
  13. American Cancer Society. How common is breast cancer? Cancer Facts & Figures 2026; revised 24 June 2026.
  14. National Cancer Institute. Financial burden of cancer care. Cancer Trends Progress Report. Bethesda, MD: National Cancer Institute.
  15. US Preventive Services Task Force. Screening for hypertensive disorders of pregnancy: final recommendation statement. JAMA. 2023;330(11):1074–1082.
  16. US Preventive Services Task Force. Screening for breast cancer: recommendation statement. JAMA. 2024;331(22):1918–1930.
  17. American College of Obstetricians and Gynecologists. Biomarker prediction of preeclampsia with severe features. ACOG Clinical Practice Update. Obstet Gynecol. 2024;143(6):e153–e154.
  18. Roche Diagnostics. Roche Elecsys sFlt-1/PlGF ratio for preeclampsia receives FDA 510(k) clearance. Press release; 13 February 2025.
  19. Policy Cures Research (now Impact Global Health). Snapshot of the R&D landscape for pre-eclampsia. Policy Cures Research; May 2023.
  20. DelveInsight. Breast Cancer Pipeline Insight 2026. DelveInsight; 2026.
  21. IQVIA. The Breast Cancer Market: Precision, Competition, and What’s Next. IQVIA; 2026.
  22. Labcorp. Labcorp introduces first trimester screening test to assess preeclampsia risk during pregnancy. Press release; 15 May 2024.
  23. Mirvie. Introducing Encompass: a breakthrough solution from Mirvie to advance care for pregnancy complications. Press release; 13 May 2025.
  24. World Economic Forum, Boston Consulting Group. Women’s Health Investment Outlook 2026. World Economic Forum; January 2026.
  25. Comanche Biopharma. Comanche Biopharma closes oversubscribed $75 million Series B financing. Press release; 17 January 2024.
  26. Mirvie. Mirvie raises $60 million funding round to shape the future of pregnancy health. Press release; 17 May 2022.
  27. National Academies of Sciences, Engineering, and Medicine. A New Vision for Women’s Health Research: Transformative Change at the National Institutes of Health. Washington, DC: National Academies Press; 2025.
  28. Gates Foundation. Gates Foundation announces catalytic funding to spark new era of women-centered research and innovation. Press release; 4 August 2025.
  29. American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 226. Obstet Gynecol. 2020;136(4):e48–e69.
  30. Pharmaceutical Technology. Comanche raises $75m to develop preeclampsia therapy. Pharmaceutical Technology; 18 January 2024.
  31. Silicon Valley Bank. Innovation in Women’s Health 2026. Silicon Valley Bank; 2026.
  32. aitiologic. Screening is the adherence intervention. aitiologic; May 2026.
  33. Ertl R, Syngelaki A, Frank O, et al. First-trimester multi-modal cell-free DNA analysis for prediction of preterm and term preeclampsia. AJOG Glob Rep. 2026;6(3):100659.